Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bingliang Chen

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Mabs|April 11, 2020
Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibodyYan Wang, Donghui Pan, Chenrong Huang, et al.
International Journal of Biological Macromolecules|January 1, 2023
Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapyYing Zhou, Haoran Shen, Min Wu, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical modelsHongyu Xue, Zhimin Zhang, Li Li, et al.
International Immunopharmacology|October 18, 2020
IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitisLi Li, Zhihai Wu, Min Wu, et al.
Andrology|January 16, 2024
MiRNA-100 ameliorates diabetes mellitus-induced erectile dysfunction by modulating autophagy, anti-inflammatory, and antifibrotic effectsBeining Li, Peng Hu, Kang Liu, et al.
Oncoimmunology|July 9, 2021
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunityHaiping Jiang, Haiqing Ni, Pan Zhang, et al.
Cancer Immunology, Immunotherapy : CII|February 21, 2020
Development and characterization of a novel anti-OX40 antibody for potent immune activationZhihui Kuang, Hua Jing, Zhihai Wu, et al.
Cancer Research|March 20, 2023
Genome-Wide Splicing Quantitative Expression Locus Analysis Identifies Causal Risk Variants for Non-Small Cell Lung CancerMeng Jin, Bo Liu, Can Chen, et al.
Nature Communications|November 5, 2021
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicityYunqian Qiao, Yangmin Qiu, Jie Ding, et al.
Cancer Immunology, Immunotherapy : CII|August 8, 2020
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicityYan Wang, Haiqing Ni, Shuaixiang Zhou, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Mabs|April 11, 2020
Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibodyYan Wang, Donghui Pan, Chenrong Huang, et al.
International Journal of Biological Macromolecules|January 1, 2023
Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapyYing Zhou, Haoran Shen, Min Wu, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical modelsHongyu Xue, Zhimin Zhang, Li Li, et al.
International Immunopharmacology|October 18, 2020
IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitisLi Li, Zhihai Wu, Min Wu, et al.
Andrology|January 16, 2024
MiRNA-100 ameliorates diabetes mellitus-induced erectile dysfunction by modulating autophagy, anti-inflammatory, and antifibrotic effectsBeining Li, Peng Hu, Kang Liu, et al.
Oncoimmunology|July 9, 2021
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunityHaiping Jiang, Haiqing Ni, Pan Zhang, et al.
Cancer Immunology, Immunotherapy : CII|February 21, 2020
Development and characterization of a novel anti-OX40 antibody for potent immune activationZhihui Kuang, Hua Jing, Zhihai Wu, et al.
Cancer Research|March 20, 2023
Genome-Wide Splicing Quantitative Expression Locus Analysis Identifies Causal Risk Variants for Non-Small Cell Lung CancerMeng Jin, Bo Liu, Can Chen, et al.
Nature Communications|November 5, 2021
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicityYunqian Qiao, Yangmin Qiu, Jie Ding, et al.
Cancer Immunology, Immunotherapy : CII|August 8, 2020
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicityYan Wang, Haiqing Ni, Shuaixiang Zhou, et al.
Pageof 5